



S04-04 OA. HIV-specific responses induced by anti-CD40 targeting antibodies

Nicolas Loof, Monica Montes, Anne-Laure Flamar, Gérard Zurawski, Amanda Cobb, J Plants, Bryan King, Sandra Zurawski, Louis Sloan, Yves Levy, et al.

► To cite this version:

Nicolas Loof, Monica Montes, Anne-Laure Flamar, Gérard Zurawski, Amanda Cobb, et al.. S04-04 OA. HIV-specific responses induced by anti-CD40 targeting antibodies. AIDS Vaccine 2009, Oct 2009, Paris, France. pp.O46, 10.1186/1742-4690-6-S3-O46 . inserm-00663584

HAL Id: inserm-00663584

<https://inserm.hal.science/inserm-00663584>

Submitted on 27 Jan 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Oral presentation

Open Access

S04-04 OA. HIV-specific responses induced by anti-CD40 targeting antibodies

N Loof^{*1}, M Montes¹, A Flamar¹, G Zurawski¹, A Cobb¹, J Plants¹, B King¹, S Zurawski¹, L Sloan¹, Y Levy² and J Banchereau¹

Address: ¹HIV Vaccine, INSERM U899-BIIR/INSERM/ANRS Center for Human Vaccines, Dallas, TX, USA and ²INSERM U841, Créteil, France

* Corresponding author

from AIDS Vaccine 2009
Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, 6(Suppl 3):O46 doi:10.1186/1742-4690-6-S3-O46

This abstract is available from: <http://www.retrovirology.com/content/6/S3/O46>

© 2009 Loof et al; licensee BioMed Central Ltd.

Background

Antibodies directed against antigen-presenting cell (APC) receptors can deliver antigens very efficiently. This receptor-targeting vaccine system facilitates the uptake, processing and presentation of extracellular antigens. In our approach, an antibody against human CD40 was fused to HIV antigens and these prototype vaccines were tested for their capacity to stimulate the expansion of HIV-specific memory T cells.

Methods

Recombinant anti-CD40 antibodies fused to HIV Gag and/or Nef proteins were tested for their capacity to bind to DCs and to stimulate expansion of HIV-specific T cells. PBMC and dendritic cells (DC) from HIV-infected patients were incubated with Gag-targeting molecules followed by anti-Gag PE secondary antibody. Binding on CD19+, CD14+ and CD11c+ cells was measured by flow cytometry. Short-term PBMC cultures (10 days) stimulated with DC-targeting vaccines in the presence of IL-2 were re-stimulated with overlapping peptides covering the total sequences of Gag and Nef, followed by multiplex cytokine (Luminex) analysis of supernatants and intracellular staining.

Results

The anti-CD40-HIV-Gag/Nef antibodies bind to B cells, monocytes and DC with a affinity similar to the parental anti-CD40 antibody. The HIV antigen-targeting vaccines displayed a high stimulation capacity *in vitro* compared

with isotype control (IgG4) fusion proteins, inducing CD4+ and CD8+ T cell responses against Gag and Nef peptides even at very low concentrations (0.01 nM). Moreover, we observed not only antigen-specific secretion of the Th1/CTL set of cytokines but also of cytokines characteristic of Th2 and IL-21 subsets. The breadth and the quality of the T cell responses observed in PBMC cultures matched responses those observed in DC-T cell co-cultures.

Conclusion

Thus CD40 is an excellent candidate for HIV vaccines based on DC targeting, as its activation not only causes maturation of APC but permits efficient presentation and cross-presentation of HIV epitopes, thereby stimulating strong recall T cell responses.